Pfizer Spins Off Esperion While Retaining Former Subsidiary’s Top Compounds
This article was originally published in The Pink Sheet Daily
Pfizer retains undisclosed stake in Esperion, which will focus on small-molecule dyslipidemia candidate.
You may also be interested in...
The recently public company completed Phase IIa studies for lead candidate ETC-1002 and intends to complete a pair of Phase IIb studies before year-end.
Plus the latest financing news from Denmark’s Symphogen, ScioDerm, Esperion Therapeutics and Intrexon.
Spun out from Pfizer five years ago, the Ann Arbor, Mich., company hopes its Phase II candidate can capture a share of the market for high-cholesterol drugs prescribed to statin-intolerant patients.